Brief: Israel Patent Office Grants New Patent Covering Enlivex's Allocetra Immunotherapy Treatment
09/03/2020 12:18
March 9 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ISRAEL PATENT OFFICE GRANTS NEW PATENT COVERING ENLIVEX’S
ALLOCETRA IMMUNOTHERAPY TREATMENT
* ENLIVEX - ALLOCETRA, AN EXPERIMENTAL THERAPY MAY
POTENTIALLY BE
AN EFFECTIVE TREATMENT TO RESTORE ORGAN FUNCTION, PREVENT
MORTALITY OF COVID-19 PATIENTS
Source text for Eikon: ID:nGNX33SVww
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment